Study summary

Azetukalner reduced focal seizures in a dose-dependent way

X-TOLE trial (XEN1101 phase 2b) · 325 people, phase 2b · Published November 2023, JAMA Neurology

52.8%median drop in monthly seizures with 25 mg, vs 18.2% with placebo

What was tested

XEN1101 (azetukalner) at three doses or placebo for 8 weeks in adults with focal seizures despite 1 to 3 medicines.

What they found

What it means

Led to the phase 3 X-TOLE program.

JAMA Neurol, via PubMed ↗ Trial record NCT03796962 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.